ERBB2 and breast cancer: NAC regimens typically combine cytotoxic agents with molecularly targeted therapies, such as anti-Human Epidermal growth factor Receptor 2 (HER2) agents or immune checkpoint inhibitors, according to BC subtype, and have demonstrated substantial clinical value in locally advanced or inoperable disease [8].